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Background: Selenium has attracted attention because of its antioxidant properties. Antioxidants protects cells
from damage. Certain breakdown products of selenium are believed to prevent tumor growth by enhancing the
immune cell activity and suppressing the development of tumor blood vessels. In this observational study, selenium
level was measured in a series of patients from Poland and Estonia to determine a correlation between levels of
this microelement and colorectal cancer risk.
Methods: A total of 169 colorectal cancer patients and 169 healthy controls were enrolled in the study after
obtaining their informed consent. Selenium level in the blood serum was measured using Graphite Furnace Atomic
Absorption Spectrometry (GFAAS). The statistical analysis was performed by Fisher’s exact test.
Results: The threshold point of selenium level was 55 μg/l and 65 μg/l for Poland and Estonia respectively, for an
increase in cancer risk. The lower levels of selenium were associated with greater risk of colorectal cancer.
Conclusions: The result reveals a significant strong association between low selenium level and the colorectal
cancer risk in both Estonian and Polish populations.
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The efficacy of selenium is related to a “U” shaped curve
in terms of the health benefits. The low levels of selen-
ium is associated with an increased risk of malignancy
[1,2]. Too much selenium (selenosis) is also linked to
higher occurrence of common diseases, such as type 2
diabetes [2] and has also been shown to be linked with
increased incidence of lung malignancy [3].
Selenium occurs naturally in the environment but with
different levels. For example, people of Central Europe
have very low exposure to selenium compared to higher
endogenous levels in North America [4]. Much emphasis
has been placed on selenium supplementation such that
in some geographical regions the average daily intake far
exceeds the requirement. In others, where background* Correspondence: marcinlener@poczta.onet.pl
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reproduction in any medium, provided the orselenium concentrations are low, supplementation should
prove to be much more beneficial in terms of overall
health benefits. Selenium supplementation will afford dif-
ferent effects across large geographical areas and poten-
tially adds to confusion about the beneficial effects of
selenium supplementation. Moreover, intake of Se varies
considerably between countries and different regions
owing largely to the variability of the Se content present in
plant foods and food chain [4].
Early detection of colorectal cancer (CRC) represents
the best approach in reducing the burden of this disease
on society. Genetic studies have been extremely useful
in identifying markers that are associated with inherited
forms of the disease. But for cases without apparent
familial history or inherited component, it remains a
challenge to identify individuals at risk of disease.
It has been reported [5] that patients with fasting
levels of selenium below 128 μg/l are much more likely
to present with one or more adenomatous polyps (OR
4.2). The same characteristics has been confirmed intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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not support a protective role for selenium [8] against the
risk of colorectal cancer. The recent SELECT trial also
indicated that supplementation with selenium did not
provide any immediate benefit [9] and indeed could re-
sult in increased prostate cancer incidence [10]. The
critical factor in the SELECT trial is the average selen-
ium level for each of the participants. In North America
the average reported selenium level ranged from 122.4
μg/l – 151.8 μg/l. In Eastern Europe the average selen-
ium level is ~70 μg/l, which is likely to have significant
consequences when manipulated by supplementation.
In this observational study, we investigated the selen-
ium concentration in a series of colorectal cancer pa-
tients from Poland and Estonia (both countries with low
selenium levels) to determine whether there was a cor-
relation between low levels of this micronutrient and
colorectal cancer.Materials and methods
Material
A total of 169 colorectal cancer patients and 169 healthy
controls were enrolled in the study after obtaining their
informed consent. There were 67 patients with colorec-
tal cancer from Polish population and 102 colorectal
cancer patients from Estonia. The matched unaffected
control for each case/patient included for the studies
were registered at International Hereditary Cancer Cen-
ter, Pomeranian Medical University of Szczecin, Poland
and the Estonian Genome Centre, University of Tartu,
Estonia. Participants were matched for year of birth (+/−
3 years) and gender. In addition, participants from the
Polish population were also matched for any malignan-
cies among 1st degree relatives.
The Table 1 shows the characteristics of the individ-
uals included in the study.Table 1 Characteristics of subjects enrolled in the study
Polish group Cases Controls
Year of birth - average 1944 1944
- range 1926 – 1973 1928 – 1971
First-degree relatives
- with colorectal cancer 9 9
- another cancer site 26 26
Estonian group
Year of birth - average 1937 1938
- range 1920-1966 1920-1965
First-degree relatives
- with colorectal cancer 3 -
- another cancer site - -Methods
The study has been conducted in accordance with the
Declaration of Helsinki and all participants signed an in-
formed consent document prior to donating a blood
sample. Furthermore, the study was approved by Ethics
Committee of Pomeranian Medical University under the
number KB-0012/73/10. The blood (~10 ml) was col-
lected from each person enrolled in the study in order
to secure the blood serum. Selenium level in blood
serum was determined using Graphite Furnace Atomic
Absorption Spectrometry (GFAAS) – Perkin Elmer.
Seronorm™ – Nycomed Pharma AS, Oslo, Norway was
used as standard to validate the measurement method.
The measurement accuracy was +/− 5% μg Se/l. Statis-
tical analysis included the comparison of the Se level
[μg/l] in each groups. Odds ratios were generated from
two-by-two tables and statistical significance was assessed
using the Fisher’s exact test. Odds ratios were calculated
for sliding windows at constant amount of selenium
concentration data points to determine the relationship
between selenium concentration and disease risk. The cal-
culations and the graphics were performed using a free
statistical software package of R version-2.13.1.
Results and discussion
Selenium levels were assayed in both the control and
colorectal cancer groups. Selenium concentration of
blood serum was plotted against odd ratio for each
group of patients from Estonia and Poland (see Figure 1).
The threshold point of selenium concentration was 55
μg/l and 65 μg/l for Poland and Estonia respectively, for
an increase in cancer risk. The lower levels of selenium
were associated with greater risk of being diagnosed with
colorectal cancer. Based on the results shown in Figure 1,
we divided the entire set of 169 cases and 169 controls
into four groups (Table 2). Colorectal cancer patients
were significantly more likely to be in the lowest selen-
ium group compared to all other groups. A gradient
effect was observed such that the number of colorectal
cancer was lower as selenium concentrations approa-
ched the highest level.
The four groups were compared to each other to fur-
ther define the correlation between selenium level and
occurrence of colorectal cancer (Table 3). There was a
gradient response, which showed the greatest effect be-
tween the groups with the lowest selenium concentra-
tion compared to the highest with OR (13.78). The
effect was observed with reducing differences in selen-
ium concentration and disease risk (see Table 3).
The results supports the consistent evidence of inverse
correlation of selenium with colorectal cancer risk in
countries with low endogenous levels of selenium i.e.
lower circulating selenium levels being associated with
the greatest risk of malignancy. A similar pilot study,
Figure 1 Selenium level and colorectal cancer risk. The relationship between selenium concentration in blood serum and the risk of
colorectal cancer is displayed in form of odds ratios at each of the selenium level, separately for Patients from Estonia (in red) and Poland (in
blue). The odds ratios are calculated for sliding windows of 30 selenium values each. The multiple regression model "lowess" is represented as a
continuous line separately for each country. The reference baseline odds ratio of 1 has been added as a dotted black line.
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lesions (colorectal adenomas) that included 451 cases
where 69% have Se concentrations <140 μg/l and 31%
with >140 μg/l, suggested a reduced prevalence of colo-
rectal adenomas at higher selenium levels [11]. The
other studies published in 1977 on selenium dietary
intakes and CRC are derived from Schrauzer and col-
leagues. In these studies comprising 27 countries evalu-
ation of the content of selenium in the diet showed an
inverse correlation between the amount of selenium in-
take and mortality caused by cancer, including cancer of
the colon and rectum. In the same study similar inverse
correlations were found between cancer mortalities and
the selenium concentrations in whole blood collected
from healthy human donors in the U.S. and different
countries [6]. The most fundamental results on the role
of selenium supplementation in cancer prevention, in-
cluding prevention of CRC, have been achieved in NPCTable 2 Selenium concentration in the colorectal cancer grou





Selenium concentration divided into groups.study (Nutritional Prevention of Cancer). This was a
randomized clinical trial designed to evaluate the effect
of selenium supplementation of 200 μg daily selenized
yeast in cancer prevention among 1312 residents of the
Eastern United States. In this study statistically signifi-
cant decrease in the incidence of cancers has been dem-
onstrated only for subgroup of subjects with baseline
selenium concentration <105 μg/l. It was observed also
that the effective prevention on selenium supplementa-
tion depends not only on its initial level in the body but
also on the cancer site. Selenium supplementation was
associated with decreased risk of prostate, colon and
lung cancers but reverse effect of increased risk was ob-
served for breast cancers [7]. The further study
performed by these researchers demonstrated that selen-
ium supplementation was associated with a significantly
reduced risk of prevalent colorectal adenoma, but only
among subjects with a low baseline selenium levelp and the healthy control group





Table 3 The odds ratios of having low selenium
compared to high selenium and the risk of colorectal
cancer
Comparison groups p OR 95% CI
I vs II 0.0231 2.537 1.16 - 5.56
I vs III <0.0001 5.22 2.48 - 11.0
I vs IV <0.0001 13.78 6.31 - 29.82
II vs III 0.0293 2.07 1.11 -3.83
II vs IV <0.001 5.43 2.82 - 10.44
III vs IV 0.0012 2.64 1.44 - 4.83
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studies coming from U.S.A. has been reported that pa-
tients with fasting levels of selenium below 128 μg/l are
much more likely to occur with one or more adenoma-
tous polyps (OR 4.2) [5]. The other study conducted at
University of North Carolina on a relatively small group of
participants (37 cases, 36 non-cases) showed that lower
plasma selenium levels were associated with occurrence of
multiple adenomas but not with adenoma size or location
[13]. These reports are in agreement with our findings,
where we have found that higher levels of Se are associ-
ated with a reduction in colorectal cancer risk.
Many authors concluded, that observations from the
SELECT study are in opposite to above findings. The SE-
LECT trial indicated that supplementation with selen-
ium did not provide any immediate benefit in cancers
prevention including CRC. It was a large, phase 3
randomized, placebo-controlled trial involving 35 535
men from 427 participating sites in the United States,
Canada, and Puerto Rico. Results of the SELECT study
showed that selenium supplementation did not reduce
prostate cancer incidence, as well as CRC [9]. However,
the trial included almost no participants within the
range of selenium status (<106 μg/l in plasma) assuring
benefit from selenium supplementation on prostate can-
cer risk [7,12].
In men in SELECT study, the IQR of baseline serum
selenium was 122·4–151·8 μg/l, which, according to the
NPC trial, put them into the category of non-significant
increased risk from selenium supplementation [2]. In
our opinion, despite negative results it is incorrect to say
that SELECT provides an evidence for the lack of
effectiveness of selenium supplementation in cancer pre-
vention. Conversely, results of SELECT confirm observa-
tions of NPC study that selenium supplementation
strongly depends on baseline selenium concentration
and is beneficial only for individuals with low selenium
level (<106 μg/l). The men who participated in SELECT
study had baseline selenium level ~136 μg/l, which is
too high to provide any protective effect of selenium
supplementation in this group [9]. Therefore results of
SELECT, even though they are extremely important, donot explain the effect of selenium on men of low selen-
ium status.
Several studies from the other countries have provided
some evidence for a beneficial effect of selenium on
CRC risk. In the study from the Canada performed on a
total of 1048 incidence cases (402 CRC) a statistically
significant inverse associations between toenail selenium
level and the risk of colon cancer for both genders com-
bined (OR, 0.42; 95% CI, 0.19-0.93; p = .009) and for
female subjects (p = .050) were observed [14]. The re-
sults of the retrospective study performed in Germany
showed, that patients with a selenium level <70 μg/l had
a significantly lower mean survival time and a lower
cumulative cancer-related survival rate than patients
with a selenium level >70 μg/l (p = 0.0009) [15]. The as-
sociation between selenium status and risk of large size
colorectal adenomas in a geographical area with a low
selenium status were described also by group from the
Spain. In this study a significant inverse association be-
tween selenium status and the diagnosis of large size
adenomatous polyps after adjusting for confounding var-
iables was found (adj. p = 0.029). Subjects with higher
selenium status (> or = 75th percentile value of 82.11
μg/l) had a lower probability to be in the adenoma group
than subjects with lower selenium status (< 82.11 μg/l,
OR = 0.17, 95% CI = 0.03-0.84) [16]. Another study
performed on 8,113 persons examined in 1972 from two
counties in Eastern Finland showed that serum selenium
of less than 45 μg/l was associated with a relative risk of
cancer of 3.1 (95% confidence interval, 1.5-6.7, p < 0.01),
including CRC [17]. Generally, several studies from Asia
also supported a protective association between selen-
ium and colorectal cancer. An example can be derived
from the study of Chinese and Japan centers. In the
study performed by Zhao et al. significantly lower selen-
ium values were observed in blood from colorectal can-
cer patients than from normal individuals [18]. Nomura
et al. demonstrated an increase in relative risk for colon
for subjects in the lowest quintile of selenium values, as
compared to the RR for subjects in the highest quintile,
(RR = 1.8) [19].
Also the previous small studies (19 stomach cancers,
25 CRC, 25 controls) performed in Poland in Upper
Silesia have shown that plasma selenium concentrations
in gastrointestinal cancer patients (37.0 +/− 11.05 ng Se/
ml or 38.4 +/− 12.6 ng Se/ml in stomach or colon cancer
patients, respectively) were significantly lower as com-
pared to the healthy age-matched control group (51.4
+/− 14.4 ng Se/ml) [20].
Some reports provided data which are in opposite to a
beneficial effect of selenium on CRC risk. In study
performed by Takata et al. no protective effect of selen-
ium on CRC was observed among postmenopausal
women recruited from 40 clinical centers across U.S. [8].
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was not observed also in the Dutch study [21]. One of
Finnish study indicated that high selenium intake and
possibly also high vitamin E intake, especially among
men, may provide protection against cancer of the upper
gastrointestinal track but not against CRC [22]. But the
latest reports are exceptions.
Generally, according to reported findings, it can be
concluded that one of the key factor affecting the
protective effect of selenium against CRC is the baseline
selenium concentration. The protective effect of supple-
mentation with selenium is beneficial in patients with
relatively low (<100 μg/l) baseline concentration of
selenium. Selenium supplementation in individuals with
its higher baseline level is not protective and can even
have an opposite effect of increasing cancer risk. Such
reasoning is consistent with the view represented in the
publication by Rayman were it is presented by the au-
thor as the “U” shaped curve [2]. Accordingly, in coun-
tries such as Poland and Estonia the risk of CRC may be
higher than in the U.S. Actually, such validation of
reported correlation is needed, however at present it is
not possible due to differences between countries in the
intensity of surveillance.
Supplementation with Se at the recommended optimal
dose is safe and has no effect. Higher than recommended
dose leads to selenosis and hence patients should be in-
formed about the maximal daily dosage of selenium.
The background levels of selenium have a profound
effect on any expected response from supplementation.
The response on supplementation will be very different
in countries with low endogenous levels of selenium in
comparison to the higher levels.
Genetic variation in the proteins that utilize Se may
affect its biological availability and population specific
differences in genetic variation may also contribute to
the responses observed [23]. Our result show greater
risk of colorectal cancer in countries with low endogen-
ous levels of selenium. Since there is also an association
with higher levels of Se, any supplementation should
be monitored to ensure that optimal levels are being
attained and maintained. It remains to be seen if Se sup-
plementation will alter colorectal cancer in countries
where endogenous Se is low.
The average Se concentration in Poland and Estonia is ~
80μg/l and colorectal cancer appears to be significantly
more frequent in persons with low Se levels. Hence, it is
not unreasonable to suggest selenium concentration as a
surrogate marker to stratify persons for colonoscopy
screening. Furthermore, it seems that in countries where
selenium levels are low (~ 75–80 μg/l) consideration
should be given to preventive measures that should in-
clude: a) screening persons for low levels of selenium; b)
offer bowel cancer screening (colonoscopy, sigmoidoscopyor faecal occult blood testing); c) increase (or decrease)
selenium to optimal levels through the use of dietary sup-
plements, d) regular (i.e. every 12 months) measurement
of selenium levels.
Conclusions
The study shows a very strong correlation between the
level of selenium in serum and the risk of colorectal can-
cer in both Estonian and Polish populations. Due to the
risk of colorectal cancer, the majority of people from the
Estonian and Polish populations should be advised to in-
crease their selenium levels to approximately 100 μg/l.
The Prospective studies will be required to elucidate:
a) possibility of dietary supplementation of selenium; b)
the use of selenium measurements as markers of risk of
colorectal cancers. Actually, assessment of selenium
levels may increase the effectiveness of many screening
programs for colorectal cancer, for example, the cost of
detecting asymptomatic colorectal cancer by colonos-
copy can be potentially reduced by targeting patients
with low selenium.
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